What is Diabeloop?
Diabeloop is a medical technology company dedicated to improving the lives of people living with Type 1 diabetes. Founded in 2015, the company's core mission is to reduce the significant mental burden associated with managing the condition, aiming to free patients from over 100 daily therapeutic decisions. Originating from a medical research project, Diabeloop was established by Dr. Guillaume Charpentier and Erik Huneker, who, along with Marc Julien, lead the company. Their expertise is complemented by strategic partnerships with key technology research players like CEA-Leti, positioning Diabeloop at the intersection of advanced technology and critical healthcare needs.
How much funding has Diabeloop raised?
Diabeloop has raised a total of $141.1M across 4 funding rounds:
Series A
$15.8M
Unspecified
$16.3M
Series B
$34M
Series C
$75M
Series A (2017): $15.8M with participation from Kreaxi, Sofimac Investment Managers, and Crédit Agricole CIB
Unspecified (2017): $16.3M, investors not publicly disclosed
Series B (2019): $34M supported by Odyssée Venture, AGIR à dom, ADAG, and CEMAG
Series C (2022): $75M featuring LBO France, Terumo Corporation, and Innovacom
Key Investors in Diabeloop
LBO France
LBO France is a prominent investment fund with over three decades of experience in private equity and venture capital, focusing on mid-cap and small-cap investments and sustainable value creation.
Innovacom
Innovacom is a venture capital firm that has been supporting digital startups since 1988, with a strong track record in various technology sectors including medical imaging and digital customer relations.
Kreaxi
Kreaxi is an investment management firm specializing in equity financing for innovative startups, providing financial support and strategic guidance during seed, acceleration, and development phases.
What's next for Diabeloop?
With its recent major strategic investment, Diabeloop is poised for accelerated expansion and further innovation in the diabetes management sector. This latest round of financing, following previous significant capital injections, indicates a strong market position and a clear path toward scaling its operations. The company's focus on developing advanced solutions for Type 1 diabetes management suggests a strategic emphasis on enhancing patient quality of life through technological advancements. Future developments are likely to involve expanding market reach, refining existing product offerings, and potentially exploring new therapeutic areas within chronic disease management.
See full Diabeloop company page
